MPDL3280A

Phase 3Small molecule

CClovis Oncology, Inc.

MPDL3280A is one of 179 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

178

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Transitional Cell CarcinomaActive, not recruiting

Anal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Transitional Cell CarcinomaPhase 2

Active, not recruiting

Anal CarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

MPDL3280A

CClovis Oncology, Inc.

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Lung Cancer

NCT02525757

Clinical

Trials by Indication[1]

Transitional Cell Carcinoma1 trial

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

Completed·QQueen Mary University of London·Phase 2·NCT02662309·96 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn·YYale University·Phase 2·NCT02495636

Small Cell Lung Cancer1 trial

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Terminated·GGiuseppe Giaccone·Phase 1/2·NCT02748889·1 enrolled

Lung Cancer1 trial

MPDL3280A With Chemoradiation for Lung Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02525757·52 enrolled

Safety and Efficacy1 trial

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Terminated·CClovis Oncology, Inc.·Phase 1/2·NCT02630186·3 enrolled

6 more indications

Nab-paclitaxel1 trial

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Completed·—·Phase 2·NCT02716038·39 enrolled

Treatment1 trial

MPDL3280A-treatment-IST-UMCG

Active, not recruiting·UUniversity Medical Center Groningen·Phase 2·NCT02478099·81 enrolled

Breast Cancer1 trial

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Completed·FFondazione Michelangelo·Phase 3·NCT02620280·278 enrolled

Anal Carcinoma1 trial

A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03519295·97 enrolled

Resistance1 trial

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting·UUniversity College, London·Phase 2·NCT02314481·50 enrolled

Metastatic NSCLC1 trial

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT02463994·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for MPDL3280A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MPDL3280A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MPDL3280A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clovis Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CClovis Oncology, Inc.

MPDL3280A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Transitional Cell Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Small Cell Lung Cancer1 trial

Lung Cancer1 trial

Safety and Efficacy1 trial

Nab-paclitaxel1 trial

Treatment1 trial

Breast Cancer1 trial

Anal Carcinoma1 trial

Resistance1 trial

Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News